(2E)-3-(2-chlorophenyl)-3-phenylprop-2-en-1-ol | 462093-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2E)-3-(2-chlorophenyl)-3-phenylprop-2-en-1-ol
• 英文别名: (E)-3-(2-chlorophenyl)-3-phenylprop-2-en-1-ol
• CAS: 462093-59-0
• 化学式: C₁₅H₁₃ClO
• 分子量: 244.721
• InChiKey: AZXZMGWZTGAJFX-JLHYYAGUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (2E)-3-(2-chlorophenyl)-3-phenylprop-2-en-1-ol 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以81%的产率得到(E)-3-phenyl-3-(2-chlorophenyl)prop-2-enyl chloride
  参考文献：
  名称：

  N-3(9)-Arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-Opioid receptor agonists. Effects on μ-Affinity of arylalkenyl chain modifications

  摘要：

  Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid mu-, delta- and K-receptors were evaluated. Several compounds (1e,i.j 2d,e,f,g,j) exhibited a p-affinity in the low nanomolar range with moderate or negligible affinity towards delta- and kappa-receptors. The representative term N-9-(3,3-diphonylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00436-9
• 作为产物：
  描述：

  ethyl (2E)-3-(2-chlorophenyl)-3-phenylprop-2-enoate 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以70%的产率得到(2E)-3-(2-chlorophenyl)-3-phenylprop-2-en-1-ol
  参考文献：
  名称：

  N-3(9)-Arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-Opioid receptor agonists. Effects on μ-Affinity of arylalkenyl chain modifications

  摘要：

  Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid mu-, delta- and K-receptors were evaluated. Several compounds (1e,i.j 2d,e,f,g,j) exhibited a p-affinity in the low nanomolar range with moderate or negligible affinity towards delta- and kappa-receptors. The representative term N-9-(3,3-diphonylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00436-9

文献信息

• [EN] NEW COMPOUNDS, THEIR PREPARATION AND USE<br/>[FR] NOUVEAUX COMPOSES, PREPARATION ET UTILISATION DE CES DERNIERS
  申请人：NOVO NORDISK AS

  公开号：WO2000063153A1

  公开（公告）日：2000-10-26

  The present invention relates to compounds of general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及一般式（I）的化合物。该化合物可用于治疗和/或预防由核受体介导的疾病，特别是过氧化物酶体增殖物激活受体（PPAR）。
• COMPOUNDS, THEIR PREPARATION AND USE
  申请人：NOVO NORDISK A/S

  公开号：EP1171414A1

  公开（公告）日：2002-01-16
• US6972294B1
  申请人：——

  公开号：US6972294B1

  公开（公告）日：2005-12-06
• N-3(9)-Arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-Opioid receptor agonists. Effects on μ-Affinity of arylalkenyl chain modifications
  作者：G Pinna

  DOI：10.1016/s0968-0896(01)00436-9

  日期：2002.6

  Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid mu-, delta- and K-receptors were evaluated. Several compounds (1e,i.j 2d,e,f,g,j) exhibited a p-affinity in the low nanomolar range with moderate or negligible affinity towards delta- and kappa-receptors. The representative term N-9-(3,3-diphonylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine. (C) 2002 Elsevier Science Ltd. All rights reserved.